Endo International has appointed Blaise Coleman as executive vice president and chief financial officer (CFO), effective December 19, 2016. Mr. Coleman has been serving as Endo's interim CFO since November 22, 2016.
Mr. Coleman joined Endo in January 2015 as vice president of corporate financial planning & analysis, and was then promoted to senior vice president, global finance operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, most recently as the CFO of the AstraZeneca/Bristol-Myers Squibb US diabetes alliance. Prior to that, he was the head of finance for the AstraZeneca global medicines development organization based in Mölndal, Sweden.
Mr. Coleman joined AstraZeneca in 2007 as senior director commercial finance for the US cardiovascular business. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in both the licenses and acquisitions and commercial finance organizations. Mr. Coleman's move to Centocor in early 2003 followed 7 years' experience with the global public accounting firm, PricewaterhouseCoopers LLP.
Source: Endo International